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ABSTRACT
Introduction: In most treated patients with
hypertension, a two or more drug
combination is required to achieve adequate
blood pressure (BP) control. In our study we
assessed whether the combination of
zofenopril ? hydrochlorothiazide (HCTZ) was
at least as effective as irbesartan ? HCTZ in
essential hypertensives with at least one
additional cardiovascular risk factor,
uncontrolled by a previous monotherapy.
Methods: After a 2-week placebo washout, 361
treated hypertensive patients [office sitting
diastolic BP (DBP), C90 mmHg], aged
18–75 years, were randomized double blind to
18-week treatment with zofenopril 30 mg plus
HCTZ 12.5 mg or irbesartan 150 mg plus HCTZ
12.5 mg once daily, in an international,
multicenter study. After the first 6 and
12 weeks, zofenopril and irbesartan doses
could be doubled in non-normalized subjects.
The primary study end point was the office
sitting DBP reduction after 18 weeks of
treatment. Secondary end points included
office systolic BP (SBP), ambulatory BP and
high sensitivity C-reactive protein (hs-CRP).
Results: The between-treatment difference for
office DBP averaged to ?1.0 (95% CI -0.4, ?0.8)
mmHg (P = 0.150), the upper limit of the 95%
confidence interval being inferior to the
protocol-defined non-inferiority limit
(3 mmHg). In the subset of patients with valid
ambulatory BP, no difference in 24-h average
DBP [n = 181; 6.7 (8.7, 4.6) zofenopril ? HCTZ
vs. 6.3 (8.8, 3.7) mmHg irbesartan ? HCTZ,
P = 0.810] and SBP reductions [11.7 (15.4, 8.0)
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vs. 12.6 (17.2, 8.0) mmHg, P = 0.758] were
observed between the two treatment groups.
hs-CRP was reduced by zofenopril ? HCTZ
[-0.52 (-1.05, 0.01) mg/L], while it was
increased by irbesartan plus HCTZ [0.97 (0.29,
1.65) mg/L, P = 0.001 between treatments].
Conclusion: In previously monotherapy-treated,
uncontrolled patients with hypertension,
zofenopril 30–60 mg ? HCTZ 12.5 mg is as
effective as irbesartan 150–300 mg plus HCTZ
12.5 mg, with the added value of a potential
protective effect against vascular inflammation.
Keywords: Ambulatory blood pressure
monitoring; Cardiology; Essential
hypertension; Hydrochlorothiazide; Irbesartan;
Office blood pressure; Zofenopril
INTRODUCTION
Arterial hypertension affects almost 30% of the
adult population worldwide [1] and is currently
considered as a major risk factor for an array of
cardiovascular and related diseases [2].
Numerous randomized, placebo-controlled
studies have conclusively demonstrated that in
patients with hypertension, blood pressure
(BP) reduction lowers the incidence of
cardiovascular morbid and fatal events [3, 4].
Large pharmacological trials have also
documented that combination therapy with
two or more drugs is required to achieve BP
control in most patients with hypertension,
particularly in those with associated
cardiovascular risk factors or at high risk for
cardiovascular events [5–8]. For these reasons,
guidelines on the management of hypertension
currently recommend the use of two drug
combinations as a first-line therapy [9, 10].
One of the most effective two drug
antihypertensive combinations is that between
an angiotensin converting enzyme (ACE)
inhibitor or an angiotensin II receptor blocker
(ARB) and a diuretic, in which the ACE inhibitor
and the ARB antagonize the counter-regulatory
system activity triggered by the diuretic, thus
improving the efficacy and tolerability of single-
drug components [11].
Zofenopril calcium, a pro-drug of the active
compound zofenoprilat, is a highly lipophilic
ACE inhibitor which has been successfully and
safely employed in the treatment of essential
hypertension [12] and acute myocardial
infarction or heart failure [13] and also in
subgroups of patients with elevated BP [14,
15]. In subjects with essential hypertension,
zofenopril has been shown to be as effective as
atenolol [16], hydrochlorothiazide (HCTZ) [17],
amlodipine [18], enalapril [19], lisinopril [20],
losartan [21], and candesartan [22].
Irbesartan is an ARB, characterized by a high
bioavailability, a long duration of action,
and a small potential for pharmacological
interactions [23]. The drug has showed a high
efficacy in lowering BP in hypertensive patients,
particularly those with renal impairment, where
it demonstrated the most remarkable evidence
of efficacy within the ARB class [24].
Comparative clinical trials performed in
mild-to-moderate hypertension showed equal
efficacy, but better tolerability of irbesartan,
compared to the other major antihypertensive
classes, including beta-blockers (atenolol),
calcium antagonists (amlodipine), ACE
inhibitors (enalapril), and renin inhibitors
(aliskiren), and superior efficacy as compared
to doxazosin [23, 24].
Both zofenopril and irbesartan have been
also successfully employed in hypertensive
patients in combination with a diuretic
[23–26]. However, since direct comparative
data on the antihypertensive efficacy and
safety of this two drug combination are
lacking and since most studies did not test the
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efficacy of the highest available dose of
zofenopril (60 mg) plus HCTZ, the present
study was devised. Irbesartan was selected as
comparator, because its efficacy was shown to
be superior to that of other common ARBs such
as losartan and valsartan [23, 24]. To comply
with the current recommendations, the patients
targeted for treatment were those with an
essential hypertension not controlled by a
previous monotherapy associated with one or
more additional cardiovascular risk factors. To
make the comparison particularly stringent,
efficacy assessment was based not only on
conventional office BP measurements taken
24 h post-dosing, but also on ambulatory
monitoring over 24 h.
METHODS
Study Population
Essential hypertension patients (sitting office
diastolic blood pressure (DBP) C90 mmHg) of
both genders, aged 18–75 years, with at least
one additional cardiovascular risk factor,
uncontrolled by previous monotherapy, were
eligible for study participation. The following
cardiovascular risk factors were considered
among the inclusion criteria [9]: (a) current
smoking; (b) elevated total cholesterol
([190 mg/dL) or specific lipid-lowering drug
treatment; (c) elevated low density lipoprotein
(LDL) cholesterol ([115 mg/dL) or specific lipid-
lowering drug treatment; (d) low high density
lipoprotein (HDL) cholesterol (\40 mg/dL in
males and \46 mg/dL in females) or specific
lipid-lowering drug treatment; (e) diabetes
mellitus controlled by diet or specific anti-
diabetic therapy (HbA1c B7.5%); (f) abdominal
obesity: waist circumference \102 cm in males
and \88 cm in females, or body mass index
(BMI) between 25 and 32 kg/m2; and (g) family
history of premature cardiovascular disease
(males at age \55 years and females at age
\65 years).
Patients were excluded if they had:
(a) secondary or malignant hypertension;
(b) isolated systolic hypertension; (c) orthostatic
hypotension [office systolic blood pressure (SBP),
drop upon standing C20 mmHg]; (d) history of
heart failure requiring medical treatment;
(e) myocardial infarction or cerebrovascular
accidents in the previous 6 months;
(f) hemodynamically significant cardiac valve
disease; (g) severe or clinically significant
systemic, renal, hepatic, neurological, or
psychiatric disease; (h) moderate-severe obesity
(BMI[32 kg/m2); (i) large (circumference[32 cm)
or tiny upper arm (circumference \24 cm); and
(j) known hypersensitivity to ACE inhibitors,
ARBs, or thiazide diuretics.
Pregnant women and breast-feeding mothers
were excluded as well. Women with
childbearing potential or within 2 years from
menopause had to practice an effective method
of birth control and were required to have a
negative urine pregnancy test.
The study was conducted according to Good
Clinical Practice guidelines and the protocol
was approved by the ethics committees of the
centers involved. All procedures followed were
in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008. Informed consent was
obtained from all patients for being included in
the study.
Study Design
This was an international, multicenter,
randomized (1:1), double-blind, parallel group
study conducted at 27 hospitals located in five
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different European countries: seven centers in
Italy, three in Greece, three in Lithuania, four in
Romania, and ten in Turkey. The study
consisted of a 2-week single-blind run-in
period during which previous antihypertensive
treatment was stopped and replaced with
placebo, followed by 18 weeks of double-blind
treatment with zofenopril or irbesartan at the
initial doses of 30 or 150 mg combined with
HCTZ 12.5 mg. Placebo and study drugs were
given orally and once daily (between 9 and 11
a.m.) with a glass of water. After the first 6 and
12 weeks of active treatment, the dose of
zofenopril or ramipril had to be doubled,
respectively, to 60 and 300 mg, if office SBP
was C140 mmHg or office DBP was C90 mmHg
in non-diabetic patients and if office SBP was
C130 mmHg or office DBP was C80 mmHg in
diabetic patients [27].
At the screening visit, informed consent was
obtained and medical history collected. At the
same visit, physical examination, a 12-lead
electrocardiography (ECG), BP and heart rate
measurements and laboratory tests (blood
count, glucose, total, LDL and HDL
cholesterol, triglycerides, uric acid, creatinine,
sodium and potassium, transaminases and
c-GT, total bilirubin, HBA1c, high sensitivity
C-reactive protein (hs-CRP), urinalysis, and
urine pregnancy tests) were carried out locally.
No centralized assessment of laboratory tests
was foreseen. Physical examination and BP and
heart rate measurements were repeated at each
visit (6, 12, and 18 weeks after randomization),
while an ECG was assessed again and laboratory
tests checked at the end of the 18 weeks of
double-blind treatment. Adverse events,
assumption of concomitant medications, and
compliance to treatment were assessed at each
visit. At the end of the placebo run-in period
and 18 weeks of double-blind treatment, BP was
measured by 24-h ambulatory monitoring.
Office Blood Pressure and Heart Rate
Measurement
Blood pressure and heart rate were measured in
the office by a validated, automatic, electronic,
upper arm sphygmomanometer (A&D UA-
767PC, A&D Company Limited, Tokyo, Japan)
[28], approximately 24 h after the last placebo
or drug intake. The arm cuff was kept at the
heart level during every BP measurement. Three
measurements, taken at 2-min intervals, after
5 min of rest in the sitting position were
averaged and used as the office BP reference
value. Blood pressure and heart rate values were
also taken after 1 and 4 min of standing.
Ambulatory Blood Pressure Measurements
Ambulatory BP monitoring was performed at
randomization and the final visit, non-
invasively, over 24 h by an oscillometric,
validated, automatic, electronic device (A&D
TM-2430, A&D Company Limited, Tokyo,
Japan) [29]. The monitoring cuff was wrapped
around the non-dominant arm and the patient
was asked to keep her/his arm still during the
automatic BP measurements. The device was
programmed to measure BP every 15 min
throughout the whole monitoring period.
Each recording started in the morning,
immediately after office BP assessment and
administration of placebo or active treatment.
Patients were then sent home, asked to resume
normal life and to come back 24 h later for
removal of the device. Results of the recording
were read by connecting the BP measuring
device to a wireless interface which sent data
to a centralized data management center
(Central Core Laboratory, Biotechmed, Varese,
Italy) through the mobile telephone network
and the web [30]. Traces had to be analyzed real
time and in case of a bad-quality recording (see
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below) the investigator was contacted by the
central core laboratory to repeat the recording
in the next 2 days, whenever possible.
Data Analysis
The primary efficacy end point of the study was
the between-treatment comparison of sitting
office DBP changes from baseline to the end of
the 18 weeks of double-blind treatment.
This was a non-inferiority trial; thus the
hypothesis was that zofenopril plus HCTZ had
to be defined as being non-inferior to irbesartan
plus HCTZ in case of a difference within
3 mmHg for DBP, with a common standard
deviation of 9 mmHg. Using a one-tailed t test
with a 0.025 significance level and an 80%
power, the estimated number of patients to be
randomized was 320 (including a 10% dropout
rate), with 160 for each treatment group.
Analysis was performed on patients valid for
intention to treat, defined as all randomized
patients receiving at least one dose of active
treatment drug and having at least one office BP
measurement after randomization. The last-
observation-carried-forward method was used
for patients prematurely leaving the study.
The per-protocol population included all
randomized patients completing the 18-week
double-blind study period without major
protocol violations and was used for
confirmatory analysis.
Secondary study end points were between-
treatment comparison of: (a) office sitting SBP
changes after 18 weeks of double-blind
treatment; (b) the percentage of patients with
a sitting office SBP \140 mmHg and DBP \90
mmHg after 18 weeks of double-blind treatment;
(c) the percentage of patients with a sitting office
SBP \130 mmHg and DBP \80 mmHg after
18 weeks of double-blind treatment; (d)
the percentage of normalized (sitting office SBP
\140 mmHg and DBP \90 mmHg) plus
responder patients (sitting office SBP reduction
C20 mmHg or DBP reduction C10 mmHg) after
18 weeks of double-blind treatment; (e) changes
in 24-h average SBP and DBP after 18 weeks of
treatment; (f) hourly averages of SBP and
DBP before and during treatment; (g) SBP and
DBP changes in the last 6 h of the dosing interval
after 18 weeks of treatment; (h) smoothness
index of SBP and DBP after 18 weeks of
treatment [31].
The analysis of 24-h BP recordings was
preceded by removal of artifacts according to
previously described editing criteria [32].
Recordings were considered valid when no
more than 1 h was missing over the 24 h and
when at least 70% of the expected
measurements were available.
Safety analysis was applied to all randomized
patients, by calculating the incidence of adverse
events and changes in laboratory data or ECG
during the study.
Between-treatment differences in mean
sitting office DBP changes at week 18 were
assessed by analysis of covariance, by adjusting
for the baseline value and considering the
center effect. Given the unbalanced
distribution of cardiovascular risk factors
between the two randomization groups, an
analysis was run taking into account the
baseline value, the country effect, and the
presence of at least one cardiovascular risk
factor among advanced age, increased waist
circumference, current smoking, alcohol
drinking, and diabetes. The latter analysis was
applied to all the secondary end points.
Comparison of normalized and normalized
plus responder patients between the two
treatment groups was performed by the Chi-
square test. Subgroup analysis by drug doses,
type of hypertension (mild or moderate), and
presence of diabetes was also made. The level of
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statistical significance was kept at 0.05
throughout the whole study. Data are shown
as mean ± SD, mean and 95% confidence
interval, and absolute (n) or relative (%)
frequency.
All data analysis was performed using SAS
Software Version 9.2 (SAS Institute Inc., NC,
USA).
RESULTS
Baseline Demographic and Clinical Data
A total of 408 patients were screened, but 47
were lost during the placebo washout period.
Thus the number of patients randomized to one
of the two treatment arms was 361. Of these
patients 327 completed the 18-week double-
blind randomized phase, while 34 discontinued
the study because of consent withdrawal
(n = 16), lack of compliance to study
procedures (n = 7), adverse events (n = 7), lack
of efficacy (n = 1), protocol violation (n = 2), or
being lost to follow-up (n = 1). A flowchart of
the patients throughout the study is presented
in Fig. 1.
Overall, 353 patients were eligible for the
intention-to-treat analysis (175 in the
zofenopril plus HCTZ and 178 in the
irbesartan plus HCTZ treatment group) and
294 for the per-protocol analysis (152 in the
zofenopril plus HCTZ and 142 in the irbesartan
plus HCTZ treatment group). 181 out of 356
patients undergoing ambulatory BP monitoring
at baseline had valid recordings and were
included in this subgroup analysis (95
randomized to zofenopril plus HCTZ and 86 to
irbesartan plus HCTZ).
As shown in Table 1, patients randomized to
zofenopril plus HCTZ displayed a higher
cardiovascular risk profile with respect to those
randomized to irbesartan plus HCTZ: they were
older, made a broader use of concomitant
therapies, and showed a larger prevalence of
additional cardiovascular risk factors besides
hypertension.
The subgroup of patients undergoing a
24-h BP monitoring and randomized to
zofenopril plus HCTZ was older than that
assigned to the irbesartan plus HCTZ group
(58 ± 9 vs. 54 ± 10 years, P = 0.005), while no
between-treatment differences were observed
for other demographic and clinical data. In
the ambulatory BP monitoring subgroup,
entry office SBP and DBP values did not
differ between the two treatment arms
(151 ± 13/96 ± 5 mmHg zofenopril plus HCTZ
and 151 ± 11/97 ± 5 mmHg irbesartan plus
HCTZ, P = 0.780 for SBP and P = 0.255 for
DBP).
Drug Dosing
The 60-mg dose of zofenopril in combination
with HCTZ 12.5 mg was taken at the end of the
study by 68.6% of patients randomized to this
drug and the 300-mg dose of irbesartan (plus
HCTZ 12.5 mg) by 61.2% of the patients
(P = 0.183). The proportion of patients under
full drug dose did not differ in the subgroup of
obese patients (77.8% zofenopril vs. 64.9
irbesartan, P = 0.135).
In the ambulatory BP monitoring subgroup,
the proportion of patients taking a higher dose
of both drugs was in line with the figure for the
main study population (72.6% zofenopril vs.
65.1% irbesartan, P = 0.275).
Sitting Office Blood Pressure
The between-treatment difference for office
DBP (primary end point) averaged to ?1.0
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(95% CI -0.4, ?0.8) mmHg (P = 0.150), with
the upper limit of the 95% confidence interval
being inferior to the protocol-defined non-
inferiority limit of 3 mmHg.
Figure 2 shows baseline-adjusted office
sitting DBP and SBP reductions in the
intention-to-treat population after correction
for the country effect and type of
cardiovascular risk factors. Office BP values
were progressively and significantly (P\0.01)
reduced by both treatment regimens during
the study. At the final evaluation (week 18),
mean sitting office DBP reduction (and 95%
confidence interval) achieved with zofenopril
combined with the diuretic was 17.6 (19.9,
15.3) vs. 15.1 (17.5, 12.6) mmHg with
irbesartan plus HCTZ, showing a difference of
-2.6 (-5.9, ?0.8) mmHg (P = 0.134) between
the two drug treatments. Office sitting SBP
reductions at the end of the study were 21.5
(24.5, 18.6) mmHg in the zofenopril and 20.6
(24.1, 17.2) mmHg in the irbesartan treatment
Fig. 1 Flow diagram of the patients through the different phases of the study
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group, with no between-treatment differences
(P = 0.691).
At the end of the study, office sitting DBP
and SBP reductions were similar with zofenopril
30 mg plus HCTZ [DBP 16.4 (18.6, 14.3) mmHg;
SBP 18.2 (21.8, 14.6) mmHg] and with
irbesartan 150 mg plus HCTZ [15.0 (17.4, 12.6)
and 22.0 (25.9, 18.1) mmHg] in the subgroup of
patients with diabetes (P = 0.366 between
groups for DBP and P = 0.115 for SBP).
Normalized and Responder Patients
Sitting office BP normalization (SBP \140 and
DBP\90 mmHg) was achieved by the end of the
18 weeks of double-blind treatment by a similar
Table 1 Demographic and clinical data of the patients of the intention-to-treat population at the time of randomization
(n = 353)
Baseline characteristics Zofenopril 30–60 mg 1
HCTZ 12.5 mg (n 5 175)
Irbesartan 150–300 mg 1
HCTZ 12.5 mg (n5 178)
P value
Age (years, mean ± SD) 56 ± 11 54 ± 11 0.024
Males (n, %) 112 (64) 99 (56) 0.108
BMI (kg/m2, mean ± SD) 28 ± 3 28 ± 3 0.357
BMI class (n, %) (kg/m2)
\25 32 (18) 33 (19) 0.962
25–29.9 89 (51) 88 (49)
C30 54 (31) 57 (32)
Waist circumference (cm, mean ± SD) 100 ± 10 97 ± 10 0.023
Concomitant diseases (n, %) 151 (86) 144 (81) 0.172
Concomitant therapies (n, %) 102 (58) 79 (44) 0.009
Type of previous antihypertensive treatment (n, %)
ACE inhibitors 68 (39) 54 (30) 0.221
ARBs 47 (27) 58 (33)
Calcium-channel blockers 37 (21) 41 (23)
Others 23 (13) 25 (14)
Diabetes (n, %) 34 (19) 29 (16) 0.442
Alcohol drinking (n, %) 81 (46) 74 (42) 0.372
Cigarette smoking (n, %) 56 (32) 45 (25) 0.163
Other CV risk factors (n, %) 143 (82) 129 (73) 0.039
Sitting ofﬁce SBP (mmHg) 152 ± 13 151 ± 12 0.549
Sitting ofﬁce DBP (mmHg) 96 ± 5 96 ± 5 0.728
Data are separately shown for the two groups of randomization and reported as mean (±SD) or absolute (n) and relative
frequency (%). The P value refers to the statistical signiﬁcance of between-treatment differences
ACE angiotensin converting enzyme, ARB angiotensin II receptor blocker, BMI body mass index, CV cardiovascular, DBP
diastolic blood pressure, HCTZ hydrochlorothiazide, SBP systolic blood pressure
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proportion of patients treated with zofenopril
plus HCTZ (79.6%) and irbesartan plus HCTZ
(79.5%, P = 0.973). The rate of normalized
patients was lower when a tighter BP goal was
considered (SBP \130 and DBP \80 mmHg):
59.3% zofenopril plus HCTZ vs. 53.6%
irbesartan plus HCTZ (P = 0.387). Finally, the
proportion of normalized or responder patients
was identical between zofenopril plus the
diuretic (88.4%) and irbesartan plus the
diuretic (88.5%; P = 0.981).
The results of the intention-to-treat analysis
on office BP changes and normalized and
responder rates were confirmed on the per-
protocol population (data not shown).
Ambulatory Blood Pressure Monitoring
Also in the population of patients with valid
ambulatory recordings, sitting office DBP and
SBP reductions were similar with zofenopril plus
HCTZ [15.4 (17.5, 13.2) and 21.2 (24.4, 18.0)
mmHg] and irbesartan plus HCTZ [16.8 (19.4,
14.2) and 23.2 (27.1/19.2) mmHg; P = 0.397 for
DBP and P = 0.458 for SBP]. Treatment-induced
24-h DBP and SBP reductions under zofenopril
plus HCTZ did not significantly differ from
those under irbesartan plus HCTZ (Table 2).
As shown in Fig. 3, both drugs reduced BP
during every hour in which the 24 h were
Table 2 Average 24-h ambulatory diastolic (DBP) and systolic blood pressure (SBP) at randomization and baseline-
adjusted reductions after 18 weeks of treatment with zofenopril ? hydrochlorothiazide (HCTZ) or irbesartan ? HCTZ
Average 24-h BP reduction Zofenopril 30–60 mg1
HCTZ 12.5 mg (n5 95)
Irbesartan 150–300 mg1
HCTZ 12.5 mg (n 5 86)
P value
24-h DBP (mmHg)
Baseline 84.8 ± 8.0 86.1 ± 7.6
Reduction with treatment 6.7 (8.7, 4.6) 6.3 (8.8, 3.7) 0.810
24-h SBP (mmHg)
Baseline 144.6 ± 14.0 142.2 ± 13.0
Reduction with treatment 11.7 (15.4, 8.0) 12.6 (17.2, 8.0) 0.758
Data are shown for the intention-to-treat population and reported as mean and 95% conﬁdence interval. The P value refers
to the statistical signiﬁcance of the between-treatment difference
BP blood pressure
Fig. 2 Baseline-adjusted ofﬁce sitting diastolic (DBP) and
systolic blood pressure (SBP) mean changes (95%
conﬁdence intervals) from baseline after 6, 12, and
18 weeks of treatment with zofenopril 30–60 mg plus
hydrochlorothiazide (HCTZ) 12.5 mg (n = 175, open
bars) and irbesartan 150–300 mg plus HCTZ 12.5 mg
(n = 178, full bars), for the intention-to-treat population.
Asterisk refers to the statistical signiﬁcance of between-
treatment differences (*P\0.05)
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divided. The drug efficacy in the last 6-h period
from the dosing interval, covering the last part
of the night sleep and the hours of awakening,
was similar for both DBP [5.6 (8.3, 3.0) vs. 5.7
(9.0, 2.4) mmHg; P = 0.969] and SBP [9.8 (14.4,
5.3) vs. 12.0 (17.7, 6.3) mmHg; P = 0.561].
Assessment of the homogeneity of the BP
control by the smoothness index, showed a
comparable persistent antihypertensive efficacy
of the two drugs over the 24 h for both DBP and
SBP (Fig. 4).
Effects on hs-CRP
In total, 91 patients had evaluable blood
samples for hs-CRP quantification. In the 51
patients treated with zofenopril plus diuretic,
hs-CRP was reduced from 1.59 ± 2.88 to
1.40 ± 2.03 mg/L, while in the 40 patients
treated with the irbesartan plus diuretic hs-
CRP remained stable during treatment (baseline
1.44 ± 2.20 mg/L; end of treatment
1.45 ± 2.17 mg/L). This resulted in a small
baseline-adjusted reduction in hs-CRP by
Fig. 3 Average hourly diastolic (DBP) and systolic blood
pressure (SBP) values at baseline (continuous line) and at the
end of the 18-week double-blind treatment (dashed lines) in
patients treated with zofenopril 30–60 mg plus
hydrochlorothiazide (HCTZ) 12.5 mg (n = 95) or
irbesartan 150–300 mg plus HCTZ 12.5 mg (n = 86).
Data are shown for the patients of the intention-to-treat
population with valid 24-h recordings (n = 181)
Fig. 4 Average smoothness index (±SD) of diastolic
(DBP) and systolic blood pressure (SBP) for zofenopril
30–60 mg plus hydrochlorothiazide (HCTZ) 12.5 mg
(n = 95, open bars) and irbesartan 150–300 mg plus
HCTZ 12.5 mg (n = 86, gray bars). Data are shown for
the patients of the intention-to-treat population with valid
24-h recordings (n = 181)
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zofenopril [-0.52 (-1.05, 0.01) mg/L] and in a
slight increase by irbesartan [0.97 (0.29, 1.65)
mg/L, P = 0.001 between treatments].
Safety and Tolerability
Laboratory and safety analyses were carried out
in all randomized patients (n = 361). A total
number of 88 (24.4%) patients reported adverse
events (48 in the zofenopril plus HCTZ and 40
in the irbesartan plus HCTZ treatment group):
126 adverse events (71 under zofenopril and 55
under irbesartan) were reported in at least 2
patients and most of them were of a mild
intensity. Seven (1.9%) patients were
withdrawn from the study due to adverse
events, all considered as drug related (4 in the
zofenopril and 3 in the irbesartan group).
Events attributed to study treatment
occurred in 26 patients (7.2%), of which 14
(7.8%) were treated with zofenopril plus the
diuretic and 12 (6.6%) with irbesartan plus the
diuretic. A total of 24 drug-related adverse
events were reported in at least two patients
with a comparable distribution between the two
study groups (10 zofenopril vs. 14 irbesartan).
The most common drug-related adverse events
observed under zofenopril were cough (4 cases),
malaise (3 cases), and headache (2 cases),
whereas dizziness (4 cases), asthenia (3 cases),
abdominal pain (3 cases), and hypotension (2
cases) were more prevalent in irbesartan-treated
patients. All these side effects may be expected
with these classes of drugs.
Treatment was accompanied either by no
change or only small and meaningless changes
in the laboratory values considered in the study.
DISCUSSION
In hypertensive patients uncontrolled by a
previous monotherapy and with additional
cardiovascular risk factors, the office DBP
reduction observed after 18 weeks of treatment
with zofenopril 30 or 60 mg plus HCTZ 12.5 mg
once daily was similar to that of irbesartan 150
or 300 mg plus HCTZ 12.5 mg once daily. This
effect was obtained with the higher drug dosage
in a slightly larger proportion of subjects treated
with zofenopril (69%) than with irbesartan
(61%), most likely because of a worse
cardiovascular risk profile in the former group.
Additionally, the antihypertensive effect of the
zofenopril 30 mg plus HCTZ 12.5 mg
combination was superior to that of the
irbesartan 150 mg plus HCTZ 12.5 mg
combination.
Approximately, 80% of patients attained
the target BP of \140/90 mmHg, 60% that
of \130/80 mmHg, and 90% were classified as
normalized or responders; such proportions
were well balanced between the two drug
treatment arms. These results strongly support
that in the majority of patients not responding
to a single antihypertensive medication,
combination treatment with two drugs,
including that between a drug acting on the
angiotensin–renin–aldosterone system and a
thiazide diuretic, may substantially increase
the chance of response [33].
The BP lowering effect of both medications
was well maintained also in subgroups of
patients, such as diabetics, known to often
show a reduced response to antihypertensive
drug treatment [34]. This result, although
limited to a small subgroup of 63 patients, also
strongly supports that ACE inhibitors or ARBs
are among the most suited first options in these
high-risk patients [9].
The good office BP control obtained with
zofenopril and irbesartan was confirmed over
24 h by ambulatory monitoring. Both drugs
displayed a similarly smooth and long-lasting
antihypertensive effect, ensuring a good BP
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coverage also in the hours farthest from the last
drug intake [35]. Interestingly, the magnitude
of the 24-h BP reduction yielded by zofenopril
and irbesartan plus the diuretic in our study was
comparable with that observed in previous
studies based on ambulatory BP monitoring
and making use of the same doses of the two
drug combinations [36, 37].
This is the first study specifically assessing
the antihypertensive efficacy of high-dose
zofenopril (60 mg) plus HCTZ 12.5 mg. In
previous studies, treatment with a 30- or
60-mg dose of zofenopril combined with
HCTZ 12.5 mg once daily was superior to
monotherapy with either agent [25, 36]. In a
dose-finding multifactorial study, the
proportions of normalized and of normalized
or responders to zofenopril plus HCTZ were
57% and 80%, respectively, for the 30-mg dose,
and 79% and 93%, for the 60-mg dose (80% and
88% in our study) [36]. In another study,
administration of zofenopril 30 mg and HCTZ
12.5 mg combination for 8 weeks to 369
patients who were not responsive to zofenopril
monotherapy resulted in an increase in the
response rate up to 64% for DBP and 53% for
SBP [26].
The benefits of the irbesartan and HCTZ
combination therapy have been demonstrated
in a number of trials in patients with mild
hypertension [38–40]. These include the
COSIMA [41] study and the INCLUSIVE [42]
study, evaluating the efficacy of the
combination in patients failing to achieve BP
control with monotherapy. In such studies,
8-week treatment with a combination of
irbesartan 150 or 300 mg and HCTZ 12.5 or
25 mg resulted in 50–70% of patients achieving
BP normalization.
This is also the first study comparing
zofenopril in combination with a thiazide
diuretic with an ARB combined with a
diuretic: previous direct comparative studies
based on zofenopril monotherapy did not
show any relevant difference in treatment
efficacy vs. an ARB-based monotherapy
regimen [21, 22]. The combination between
irbesartan and a thiazide diuretic has also never
been directly compared against that of an ACE
inhibitor plus a diuretic, while evidence from
comparative trials vs. an ACE-inhibitor
monotherapy is available: in these studies
irbesartan monotherapy at doses ranging
between 75 and 300 mg was as effective in
lowering office BP and achieving BP control as
enalapril [43–46] or fosinopril [47].
Our study also explored the possible positive
effect of zofenopril and irbesartan on markers of
vascular inflammation. As a matter of fact, the
results of epidemiological and clinical studies
support a pivotal role for inflammation in all
phases of atherosclerosis, from endothelial cell
dysfunction to the culmination in acute
coronary syndrome [48]. In our hypertensive
subjects, treatment with zofenopril plus HCTZ
reduced hs-CRP, while this was not the case for
irbesartan-treated patients. This is the first
evidence of such an effect for zofenopril and it
strongly supports previous findings in patients
with hypertension that treatment with
zofenopril may be associated with a reduction
in oxidative stress, an improvement in the nitric
oxide pathway, and an anti-inflammatory
vasculoprotective effect [49]. The above results,
although based on small numbers, allow
speculating that the sulfhydryl ACE-inhibitor
zofenopril, in addition to ensuring BP control,
may contribute to slow down the development
of atherosclerosis.
Both combination treatments were well
tolerated, with a very limited number of drug-
related adverse events. As expected, the
combination containing zofenopril was
associated with a slightly larger incidence of
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cough, while dizziness or asthenia were more
commonly reported by irbesartan-treated
patients. Other adverse drug reactions were
well balanced between the two groups and the
overall tolerability profile of zofenopril and
irbesartan was comparable with that in
previous reports [25, 50, 51].
The results of our study deserve some notes
of caution. First, the sample size of patients with
valid ambulatory BP recordings approximated
50% of that included in the primary study end-
point analysis. Unfortunately, this occurred
because many recordings were missing or
qualitatively inadequate. However, in the
ambulatory BP monitoring subgroup, the
effect of both drugs on office BP was
comparable with that observed for the whole
study population, indicating that the two
populations were homogeneous. Second, the
estimated standard deviation of the difference
(9 mmHg) may have been too large. However, a
post hoc sample size calculation, using a smaller
value (5 mmHg) and retaining the same number
of subjects, returned a power close to 100%,
thus confirming the appropriateness of our
study sample size. Third, analyses on
subgroups such as diabetics were not
conceived at the time the study was planned.
Consequently, we cannot exclude that our
findings regarding such a subgroup might be
the result of chance. Fourth, the population
with valid hs-CRP assessment was smaller than
the main study population, though the effect
observed in zofenopril-treated patients for this
inflammatory marker is in line with findings
from previous studies [49]. We also attempted
an exploratory analysis on patients with
abnormal hs-PCR levels ([3 mg/L) [52, 53], but
since only 11 patients fell in this group we
could not obtain any reliable result. Finally, we
did not foresee adjustment of randomization in
the two groups by specific comorbidities, and
since the two groups differed in several
comorbid features at baseline we cannot
exclude that some drug effects might be
related to these factors. For these reasons we
settled to adjust the comparison, whenever
possible, for these source of unbalance.
CONCLUSION
The present pharmacological trial demonstrated
that the combinations of zofenopril and HCTZ
and that of irbesartan and HCTZ both provide
similarly effective, prolonged and well-tolerated
control of BP in hypertensive patients not
controlled by previous monotherapy and with
one or more additional cardiovascular risk
factors. The reduction in hs-CRP observed with
treatment with zofenopril plus the diuretic
suggests an additional beneficial effect of
this combination therapy on vascular
inflammation.
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